Countervail Awarded $225,000 SBIR Phase I Grant For Diagnostic Test Development February 6, 2018 • Bill Basinger • Agriculture, Diagnostic Tests, Funding, Grants Read More »
Preclinical Toxicology Study Shows Excellent Results On Countervail’s Lead Antidote Candidate January 2, 2018 • admin • Funding, General News, Grants, Pharmaceuticals Read More »
Countervail competes and is selected for participation in the SBIR sponsored Commercialization Acceleration Program (CAP). October 14, 2015 • admin • Funding, General News Read More »
Countervail receives additional $630,000 SBIR Fast Track Phase II grant award for continued development of AverTox® (galantamine) for pre-exposure administration to protect against soman toxicity. August 3, 2015 • admin • Funding, General News Read More »
Countervail Corporation presents significant results of orally dosed AverTox (galantamine) for improved survival from exposure to lethal levels of soman at the CounterACT Symposium held at the New York Academy of Sciences. June 17, 2015 • admin • Funding, Grants Read More »
Countervail receives additional $845,000 SBIR Fast Track Phase II grant award for continued development of AverTox® (galantamine) for pre-exposure administration to protect against soman toxicity. May 29, 2015 • admin • Funding, General News, Military, Pharmaceuticals, Uncategorized Read More »
Countervail Corporation presents significant results of i.m. dosed AverTox (galantamine) for improved survival from exposure to lethal levels of soman at the CounterACT Symposium held in Denver Colorado. June 7, 2014 • admin • Funding, General News Read More »
Countervail receives $981,000 SBIR Fast Track Phase II grant award for continued development of AverTox® (galantamine) for pre-exposure administration to protect against soman toxicity. December 7, 2013 • admin • Funding, Grants Read More »
Countervail Corporation Receives Additional $5.4 Million from BARDA For Continued Development of Medical Countermeasure to Nerve Agents October 25, 2013 • admin • Funding, General News, Pharmaceuticals Read More »
Countervail Corporation Awarded Additional $343,000 SBIR Phase II Grant for Continued Development of Medical Countermeasure to Nerve Agents September 9, 2013 • admin • Funding, Grants Read More »